-
公开(公告)号：US5139954A
公开(公告)日：1992-08-18
申请号：US525060
申请日：1990-05-18
IPC分类号： C04B35/465 , C07K14/415 , C12N15/82 , G11B5/10
CPC分类号： C07K14/415 , C04B35/465 , C12N15/8234 , C12N15/8238 , C12N15/8273 , G11B5/10
摘要： The preparation and use of nucleic acid promoter fragments homologous to the Em gene of wheat to bring the expression of selected genes in plants under external control are described. The Em promoter fragment is responsive to abscisic acid (ABA) and other compounds possessing ABA-like activity. Through transformation of protoplasts and plant cells with recombinant DNA constructs incorporating such promoter fragments, operably linked selected genes are expressed in response to ABA and compounds possessing ABA-like activity. The application of such promoter fragments and constructs to transient assay systems to predict the likelihood of stable transformation in plants is disclosed.
摘要翻译： 描述了与小麦的Em基因同源的核酸启动子片段的制备和使用，以在外部控制下使所选择的基因在植物中的表达。 Em启动子片段对脱落酸（ABA）和具有ABA样活性的其它化合物有反应。 通过用包含这种启动子片段的重组DNA构建体转化原生质体和植物细胞，可操作地连接的选择的基因是响应于ABA和具有ABA样活性的化合物而表达的。 公开了将这种启动子片段和构建体应用于瞬时测定系统以预测植物中稳定转化的可能性。
-
2.发明授权Inhibition of pathogenic agents including α6β1 integrin receptor or α6β4 integrin receptor at a surface 失效包括α6和bgr1整联蛋白受体或α6和bgr4整合素受体在表面的致病因子的抑制公开(公告)号：US07838000B2
公开(公告)日：2010-11-23
申请号：US11440746
申请日：2006-05-25
申请人： Thomas R. Scott , Heather P. Borick , Ginger A. Swire-Clark , William R. Marcotte, Jr. , Ashby B. Bodine
发明人： Thomas R. Scott , Heather P. Borick , Ginger A. Swire-Clark , William R. Marcotte, Jr. , Ashby B. Bodine
CPC分类号： C07K14/78 , A61K38/00 , A61K38/1777 , C07K2319/00
摘要： Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.
摘要翻译： 公开了治疗剂和治疗方法，其使用针对致病病原体的疾病的试剂在病原体表面包含α6和bgr1整联蛋白受体和/或α6＆bgr4整联蛋白受体。 在一个实施方案中，该疾病可以是乳腺癌。 所公开的治疗剂包括包含已经显示结合α6和bgr1整联蛋白受体和α6和bgr4整联蛋白受体的层粘连蛋白-5α3链的至少一部分G结构域的多肽。 在一个实施方案中，治疗剂可以是其中层粘连蛋白-5α3链多肽化学结合到另一种可用于破坏或中和病原体的材料的融合或嵌合物质。
-
搜索结果
2 条记录 (耗时 0.021 秒)